摘要
抗炎治疗是降低动脉粥样硬化性心血管疾病(ASCVD)患者心血管残余风险的重要策略。低剂量白细胞介素2通过增加调节性T细胞和Ⅱ型固有淋巴细胞的数量,提高其功能,从而抑制动脉粥样硬化的发生和发展。随着更多研究证实低剂量白细胞介素2在ASCVD抗炎治疗中的有效性和安全性,其有望成为ASCVD抗炎治疗的新选择。
Anti-inflammatory therapy is an important strategy to reduce the residual risk of cardiovascular events in patients with atherosclerotic cardiovascular disease.Low dose interleukin-2 inhibits the occurrence and progression of atherosclerosis by increasing both the number and function of regulatory T cells and type 2 innate lymphoid cells.As more studies validate the efficacy and safety of low-dose interleukin-2 in the anti-inflammatory treatment of atherosclerotic cardiovascular disease,it is emerging as a promising new therapeutic option.
作者
孙爽
崔淯夏
陈红
宋俊贤
Sun Shuang;Cui Yuxia;Chen Hong;Song Junxian(Department of Cardiology,Peking University People’s Hospital,Center for Cardiovascular Translational Research,Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction,Beijing 100044,China)
出处
《中国心血管杂志》
北大核心
2024年第4期375-378,共4页
Chinese Journal of Cardiovascular Medicine
